The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
 
Khanh Tu Do
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; Seagen
Research Funding - Lilly (Inst)
 
John L. Hays
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Alice P. Chen
No Relationships to Disclose
 
Geraldine O'Sullivan
No Relationships to Disclose
 
Jeffrey G. Supko
No Relationships to Disclose
 
Kristin Beebe
No Relationships to Disclose
 
Len Neckers
No Relationships to Disclose
 
Jane B. Trepel
No Relationships to Disclose
 
Min-Jung Lee
No Relationships to Disclose
 
Courtney Gannon
No Relationships to Disclose
 
Alona Muzikansky
Consulting or Advisory Role - Sofregen
 
Susana M. Campos
Consulting or Advisory Role - Clovis Oncology
 
Elizabeth Downey
No Relationships to Disclose
 
Andrew Wolanski
No Relationships to Disclose
 
Jennifer Hedglin
No Relationships to Disclose
 
Fernanda Irene Arnaldez
Employment - Novartis
Stock and Other Ownership Interests - Kite, a Gilead company
 
James H. Doroshow
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Astex Pharmaceuticals; Bayer; Bicycle Therapeutics; Cybrexa Therapeutics; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology